Stable coronary artery disease Circulatory System Chronic ischaemic heart disease
Conditions
Interventions
Arm 1: Atorvastatin (oral) 80 mg per day for 8 weeks
Arm 2: Atorvastatin (oral) 10 mg + ezetimibe (oral) 10 mg per day for 8 weeks
Ultrasonic measurements of endothelial function were carried out at
Sponsors
Johannes Gutenberg-University Mainz (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, over 18 years old 2. Angiographic, documented coronary heart disease with: a. Generalized wall irregularities (stenosis 50% 3. Endothelial dysfunction with flow-dependent dilation of the brachial artery of 100 mg/dl 5. Written consent of the patients for participation in the study
Exclusion criteria
Exclusion criteria: 1. Acute coronary syndrome 2. Stroke or peripheral revascularisation within 12 weeks before study enrolment 3. Known intolerance towards HMG CoA reductase inhibitors or ezetimibe 4. Clinically significant valvular disease 5. Hypertrophic obstructive cardiomyopathy 6. Sustained ventricular arrhythmias 7. Syncope within four weeks before the study 8. Severe respiratory disease 9. Unstable diabetes mellitus requiring frequent adjustments in insulin doses 10. Known hypothyroidism 11. Known hyperthyroidism 12. Gastrointestinal disorders (such as Crohn's disease), which could lead to decreased absorption of the study drug 13. Chronic liver disease 14. History of pancreatitis 15. History of organ transplantation 16. Clinically significant heart failure with left ventricular ejection fraction of 180 mmHg and/or diastolic blood pressure >105 mmHg despite antihypertensive therapy 19. Elevated serum creatinine of >2.0 mg/dL or known nephrotic syndrome 20. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times above the upper normal limit 21. Triglyceride level >400 mg/dl 22. Treatment with an HMG CoA reductase inhibitor during the last three months 23. Treatment with ezetimibe during the last three months 24. Initiation of treatment with an angiotensin converting enzyme (ACE) inhibitor, AT1-receptor antagonist, or calcium channel blocker within the past four weeks 25. Treatment with fibrates or colestipol during the last three months 26. Current treatment with macrolide antibiotics, niacin or antimycotics of azole type 27. Expected problems with compliance or follow-up visits (no fixed residence, alcohol or drug abuse, history of failure of medical advice, psychiatric diseases, etc.) 28. For women: pregnancy, breast feeding or possible pregnancy (women of childbearing age on an acceptable method of contraception may be included) 29. Simultaneous participation in another study 30. Therapy with another investigational product within a period of 30 days before the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of treatment on the absolute change (in percentage) in flow-mediated dilation (FMD) at 8 weeks compared to baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of treatment, at 8 weeks compared to baseline, on the following: 1. Absolute change (in percentage) in nitroglycerin-mediated dilation (NMD) 2. Absolute change in LDL cholesterol plasma concentration 3. Absolute change in C-reactive protein plasma concentration 4. Absolute change in uric acid plasma concentration 5. Absolute change in 8-iso-prostaglandin F2 alpha urine concentration | — |
Countries
Germany
Outcome results
None listed